An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis
Status:
Terminated
Trial end date:
2013-12-03
Target enrollment:
Participant gender:
Summary
This long-term, interventional, open-label extension study will evaluate the safety and
efficacy of RoActemra/Actemra (tocilizumab) in patients from Poland and Russia with
polyarticular-course juvenile idiopathic arthritis who completed the WA19977 study. Patients
will receive RoActemra/Actemra 8 mg/kg every 4 weeks. The anticipated time on study treatment
is 104 weeks.